Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of NT0102 in Children (Ages 6 to 12 Years) With Attention-Deficit Hyperactivity Disorder

Next Previous
X
Search
Trial Profile

A Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of NT0102 in Children (Ages 6 to 12 Years) With Attention-Deficit Hyperactivity Disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Neos Therapeutics

    • Most Recent Events

    • 10 Jan 2018 According to a Neos Therapeutics media release, results from this trial will be presented at the 2018 Annual Meeting of the American Professional Society of ADHD and Related Disorders (APSARD).
    • 19 Jun 2017 According to Neos Therapeutics media release, based on the results from this study the U.S. FDA approved Cotempla XR-ODT orally disintegrating tablet for the treatment of attention-deficit/hyperactivity disorder (ADHD) in patients 6 to 17 years old.
    • 19 Jun 2017 Results published in the Neos Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top